Why our pharmaceutical sector ignores its frontline workforce

The pharmaceutical industry has emerged as one of Bangladesh's most promising sectors, producing medicines that meet more than 97 percent of domestic demand and crossing $2 billion in exports. It is a rare success story in a time when economic uncertainty casts shadows across other industries. Ambitions to stand shoulder to shoulder with India and China are being voiced, and new markets from Africa to Latin America are already on the radar. But there is a fragile foundation beneath this optimism: the frontline workforce that makes the industry function is often forgotten, undervalued, and left without dignity.

Every prescription written by a doctor, every hospital order placed, and every pharmacy shelf stocked is linked through the work of representatives. They are not merely promoters. They carry scientific knowledge from laboratories to clinics, bridging the gap between research and patient care. Without them, the supply chain is broken. Factories may continue to produce, but medicines will not reach those who need them. The representatives are the living bridge of this sector, and undermining that bridge weakens the entire structure.

The contradiction is glaring. While the industry aspires to global recognition, its representatives often work from dawn until midnight, seven days a week, for salaries that remain below Tk 30,000. Rising transport fares and food prices eat into what little they earn. There is no structured promotion system, no job security, and in most cases no recognition of their professional identity. During the pandemic, these workers risked their health to ensure uninterrupted medicine supply, yet once the crisis passed, their contribution was quickly erased from memory. Such disregard is not just unjust-it is unsustainable for a sector that hopes to achieve world-class status.

Bangladesh cannot hope to compete globally while maintaining such a weak link in the chain. A demoralized workforce cannot drive expansion into competitive markets. The representatives are the very people who expand domestic penetration, explain formulations to physicians, and maintain trust in products. If they are overworked, underpaid, and undervalued, then the dream of becoming a pharmaceutical hub will collapse under the weight of its own neglect.

There are practical solutions. A minimum wage benchmark that reflects inflation is not a luxury but a necessity. Allowances for transport and meals must be introduced to cope with rising living costs. Written job security contracts and structured promotion pathways are essential to retaining skilled representatives who otherwise leave in frustration. Weekly leave must be recognized, as should the association that gives these workers a collective voice. These are not indulgent demands. They are the very standards of professional dignity required in any modern industry.

Policymakers and industry leaders should remember that other export-driven sectors in Bangladesh have learned painful lessons from neglecting their workforces. The garment industry, for example, faced international criticism and compliance pressure when working conditions were ignored. Pharmaceuticals cannot afford to make the same mistake. A single scandal involving labor practices could jeopardize international credibility, disrupt export opportunities, and erode trust in Bangladesh's ability to deliver on quality and responsibility.

Global competition is unforgiving. India, China, and even smaller emerging economies are racing ahead not only because of technological capacity but also because of structured labor management and professional recognition. If Bangladesh wishes to challenge these players, it must build a holistic foundation where both innovation and workforce welfare are prioritized. Medicines cannot carry the label "Made in Bangladesh" proudly abroad if the people ensuring their delivery at home are stripped of dignity.

The larger economic picture also reinforces this urgency. Bangladesh needs to diversify beyond garments to stabilize its reserves and strengthen its export basket. Pharmaceuticals can be that second engine, but only if the sector is built on strong foundations. An exploited workforce cannot drive innovation, cannot maintain trust, and cannot sustain the long hours required to compete globally. Empowerment is not charity; it is strategy.

The path forward is clear. The government, regulators, and industry owners must coordinate to implement reforms that institutionalize fair wages, secure contracts, and proper recognition. Such steps will not only motivate workers but also improve productivity, reduce turnover, and attract global partners who value compliance and professionalism. Without them, the lofty promises of becoming a global pharmaceutical hub will remain empty rhetoric.

Bangladesh has the opportunity to transform its pharmaceutical sector into a pillar of the economy. But history shows that no world-class industry has ever been built while ignoring those at the frontline. The lesson is simple and unavoidable: empower representatives, and the sector will thrive; neglect them, and progress will stall.

Pharmaceutical representatives are not an afterthought. They are the foundation upon which growth depends. For the nation to fulfill its ambition, decisive action must be taken now to ensure respect, recognition, and rights for those who hold the sector upright. Anything less will risk eroding one of the country's most promising industries before it reaches its true potential.